AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00891033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade)
Description: During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
Study NCT00891033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
Study NCT00463853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell therapy
Study NCT00463853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG
Study NCT00463853 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CMRI
Study NCT03194997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: The Dance intervention will be performed with belly dance methods. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
Study NCT03194997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The Pilates intervention will be performed using specific exercises of Pilates Methods. During the classes it will be used thera band, toning ball and pilates ball. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
Study NCT01246089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab injection
Description: Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
Study NCT02633436 — intervention group
Intervention type: OTHER
Intervention: SLC1A5 expression
Description: To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
Study NCT01075477 — intervention group
Intervention type: DRUG
Intervention: rituximab [Mabthera/Rituxan]
Description: As prescribed by physician
Study NCT00727740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
Study NCT00727740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension
Description: A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
Study NCT02263807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MPFL Group
Description: MPFL reconstruction or standard treatment followed by physiotherapy
Study NCT02263807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Arthroscopy followed by active rehabilitation
Study NCT02263807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Arthroscopy followed by active rehabilitation
Study NCT04417205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate Rich Breakfast
Description: Participants will be asked to consume the provided carbohydrate rich breakfast before 1000h daily for 28 days.
Study NCT04417205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein enriched breakfast
Description: Participants will be asked to consume the provided whey protein enriched breakfast before 1000h daily for 28 days.
Study NCT04678739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir 100 IV Infusion as a lyophilized powder
Study NCT04678739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Actemra IV Infusion
Study NCT03540277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Prevention Program young In Favor of Myself, active parents
Description: Prevention program: young In Favor of Myself, with parent participation
Study NCT03540277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Prevention Program young In Favor of Myself, no parental involvement
Description: Prevention program: young In Favor of Myself, without parent participation
Study NCT03042403 — intervention group
Intervention type: OTHER
Intervention: Breath stacking
Description: During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
Study NCT00992342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03893787
Description: oral solution, 5 mg, QD for 14 days
Study NCT01024361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
Study NCT01722032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Childhood Obesity
Study NCT02400892 — intervention group
Intervention type: OTHER
Intervention: TTE Bubble Study
Description: Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
Study NCT00581061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesicare
Description: Vesicare will be taken daily for one or three months, depending on symptoms of subject.
Study NCT06252467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy
Description: Phototherapy treatment (Photobiomodulation therapy or placebo) was performed using a Photobiomodulation therapy device (Vectra Genisys Systems, Chattanooga Group, Dallas, TX, USA). The cluster probe consisted of five low-level laser therapy diodes (850 nm) and 28 light emitting diodes therapy (670 nm, 880 nm, and 950 nm). Photobiomodulation therapy was applied in nine sites of each quadriceps femoris muscle~. A dosage of 15 J per site led to a total energy of 135 J per thigh, effectively increasing cycling performance in a previous study. We chose to apply Photobiomodulation therapy specifically to the quadriceps femoris because this muscle group is of utmost significance in generating torque and propelling the pedaling cycle. Its pivotal role in cycling performance made this muscle a prime target for the Photobiomodulation therapy intervention in our study.
Study NCT06252467 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Photobiomodulation
Description: The placebo treatment was performed in exactly the same manner as the Photobiomodulation therapy treatment, but with the device switched off, and the cluster was held stationary in contact with the skin at a 90° angle, with light pressure on the skin. The total application time of Photobiomodulation therapy or placebo was \~5 min for both limbs (9 points per thigh = 18 points × 16 s per point) before each time-to-exhaustion test.
Study NCT00992342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03893787
Description: oral solution, 15 mg, QD for 14 days
Study NCT02303834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure Ventilation (CPAP)
Description: A mask worn over the nose that delivers air under slight pressure.
Study NCT01796301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romozosumab
Description: Administered by subcutaneous injection once a month.
Study NCT00992342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03893787
Description: oral solution, 50 mg, QD for 14 days
Study NCT02111863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study NCT02111863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
Study NCT02111863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
Study NCT02111863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)
Description: On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
Study NCT01820884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TH
Description: Total hysterectomy
Study NCT01820884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TH/BSO
Description: Total hysterectomy and bilateral salpingo-oophorectomy
Study NCT01820884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BPLND
Description: bilateral pelvic and para-aortic lymph node dissection
Study NCT01820884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BPLND
Description: bilateral pelvic and para-aortic lymph node dissection
Study NCT02977390 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passive leg raise
Description: By tilting the patient's bed from sitting 45 degrees to supine with legs tilted up 45 degrees we recruit the blood volume in the legs and can measure a reversible fluid challenge on stroke volume.
Study NCT02637323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Single 5 mL IA injection
Study NCT02637323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40
Description: Single 1 mL IA injection
Study NCT00268372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT00268372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00268372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00268372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Study NCT00268372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT00268372 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT01796301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Administered by subcutaneous injection once a day.
Study NCT01825577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Methylphenidate
Description: 2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
Study NCT01425177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline Irrigation
Description: After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
Study NCT03671577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Closer Friendships
Description: Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
Study NCT02168348 — intervention group
Intervention type: OTHER
Intervention: biological examination at consultations at 3 and 6 months
Study NCT01882764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004
Description: Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given HMPL-004 orally three times per day with total daily dose of 1800 mg for 52 weeks.
Study NCT01882764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given Placebo orally three times per day with total daily dose of 1800 mg for 52 weeks.
Study NCT03221179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO7049665
Description: A single ascending dose (starting dose 1.5 micrograms \[mcg\])of RO7049665 will be administered SC.
Study NCT03221179 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered SC once.
Study NCT02915250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® Combo
Description: Injection of BioChaperone® Combo
Study NCT01357642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine inhalation aerosol
Description: Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
Study NCT01357642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for epinephrine inhalation aerosol, formulation without epinephrine
Study NCT02915250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix25
Description: Injection of Humalog® Mix25
Study NCT02915250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Injection of Humalog®
Study NCT02915250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Injection of Lantus®
Study NCT02915250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection of 0.9% NaCl
Study NCT02915250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Injection of 0.9% NaCl
Study NCT01357642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine inhalation aerosol
Description: epinephrine inhalation aerosol, 220 mcg/inhalation, 2 inhalations QID at 4-6 hour intervals
Study NCT00292097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early tracheostomy
Description: early conversion - less than or equal to 72 hours
Study NCT00292097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late tracheostomy
Description: Late conversion (10-14 days)
Study NCT02595372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT04600986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated dose of GnRH agonist
Description: 0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
Study NCT04600986 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Repeated dose of GnRH agonist
Description: 0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
Study NCT00561106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone- valacyclovir
Description: prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
Study NCT00561106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone-placebo
Description: prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
Study NCT02464605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SEL-037 (pegsiticase)
Description: Intravenous infusion of SEL-037
Study NCT03242902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy intensity 1
Description: Exposure to white light (10.000 lux) in the morning
Study NCT03242902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light therapy intensity 2
Description: Exposure to white light (10-20 lux) in the morning
Study NCT02688530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Saline
Study NCT02688530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dexamethasone 4mg
Study NCT02688530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dexamethasone 6mg
Study NCT02688530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Dexamethasone 8mg
Study NCT02337621 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01540942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrition treat
Description: intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;\[W=weight（Kg）；H=height（cm）；A=age（year）\]
Study NCT01540942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: bowel resection
Study NCT02977767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conversational hypnosis
Description: Conversational hypnosis starts since the enter of the nurse in patient's room and last since the nurse leaves the room. Change of canula is performed under conversational hypnosis.
Study NCT01769378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SQ
Study NCT01108237 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TruMatch™ Personalized Solutions
Description: TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.
Study NCT01108237 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Total Knee Arthroplasty with Conventional Instrumentation.
Description: Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
Study NCT00039481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00039481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV
Study NCT00039481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00039481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00039481 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00039481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00039481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00777335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat - LBH589
Description: Solution for infusion - 25mg/5ml
Study NCT00777335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat - LBH589
Description: Hard gelatine capsules - 5mg and 20 mg
Study NCT03570268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group: Education
Description: Participants in the experimental intervention group received an educational program and tailored home exercises.
Study NCT03570268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Usual care
Description: Participants allocated to the control group received stretching exercises.
Study NCT04654559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Unobtrusive data collection using wearable non-invasive sensors
Description: Two wearable non-invasive sensors will be mounted to the patients skin (lateral rib cage and foot). These wearable non-invasive sensors are measuring unobtrusively skin based parameters (no diagnosis will be made), which will be used for fever detection algorithm development..
Study NCT03285555 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STRATIFIX
Description: STRATIFIX symmetric PDS Plus; Stratifix knotless suture
Study NCT03285555 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VICRYL
Description: Vicryl #1
Study NCT01769378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SQ
Study NCT01769378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Administered PO
Study NCT01769378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Administered PO